Non-alcoholic fatty liver disease in children now: Lifestyle changes and pharmacologic treatments

Nutrition

Volumn 28, Issue 7-8, 2012, Pages 722-726

  Alisi, Anna ^a   Nobili, Valerio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Children; Fibrosis; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Steatosis; Treatment

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; FATTY ACID; INSULIN SENSITIZING AGENT; LIPID; METFORMIN; OMEGA 3 FATTY ACID; PLACEBO; URSODEOXYCHOLIC ACID;

BODY MASS; CELL PROTECTION; CHILD; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; EXERCISE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TISSUE INJURY;

ADOLESCENT; AGE OF ONSET; CHILD; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIFE STYLE; LIPOTROPIC AGENTS; PPAR GAMMA; PREVALENCE;

EID: 84862209977     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2011.11.017     Document Type: Review

References (50)

1. Brunt E.M. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7:195-203.
2. Aly F.Z., Kleiner D.E. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol 2011, 18:294-300.
3. Hesham A-Kader H. Nonalcoholic fatty liver disease in children living in the obeseogenic society. World J Pediatr 2009, 5:245-254.
4. Alisi A., Manco M., Vania A., Nobili V. Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009, 155:469-474.
5. Sundaram S.S., Zeitler P., Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr 2009, 21:529-535.
6. Feldstein A.E., Charatcharoenwitthaya P., Treeprasertsuk S., Benson J.T., Enders F.B., Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58:1538-1544.
7. Hesham A-Kader H. Nonalcoholic fatty liver disease in children living in the obeseogenic society. World J Pediatr 2009, 5:245-254.
8. Nobili V., Alkhouri N., Bartuli A., Manco M., Lopez R., Alisi A., et al. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res 2010, 67:665-670.
9. l'Allemand-Jander D. Clinical diagnosis of metabolic and cardiovascular risks in overweight children: early development of chronic diseases in the obese child. Int J Obes (Lond) 2010, 34(Suppl 2):S32-S36.
10. Barshop N.J., Sirlin C.B., Schwimmer J.B., Lavine J.E. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008, 28:13-24.
11. Lam B., Younossi Z.M. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010, 3:121-137.
12. Nobili V., Carter-Kent C., Feldstein A.E. The role of lifestyle changes in the management of chronic liver disease. BMC Med 2011, 9:70.
13. Pinzani M. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. Dig Dis 2011, 29:243-248.
14. Alisi A., Nobili V. Nonalcoholic fatty liver disease: targeted therapy in children-what is the right way?. Nat Rev Gastroenterol Hepatol 2011, 8:425-426.
15. Thoma C., Day C.P., Trenell M.I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012, 56:255-266.
16. Elias M.C., Parise E.R., de Carvalho L., Szejnfeld D., Netto J.P. Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition 2010, 26:1094-1099.
17. Ricci G., Canducci E., Pasini V., Rossi A., Bersani G., Ricci E., et al. Nutrient intake in Italian obese patients: relationships with insulin resistance and markers of non-alcoholic fatty liver disease. Nutrition 2011, 27:672-676.
18. Della Corte C., Alisi A., Iorio R., Alterio A., Nobili V. Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opin Pharmacother 2011, 12:1901-1911.
19. Vos M.B., McClain C.J. Nutrition and nonalcoholic fatty liver disease in children. Curr Diab Rep 2008, 8:399-406.
20. Tock L., Prado W.L., Caranti D.A., Cristofalo D.M., Lederman H., Fisberg M., et al. Nonalcoholic fatty liver disease decrease in obese adolescents after multidisciplinary therapy. Eur J Gastroenterol Hepatol 2006, 18:1241-1245.
21. Nobili V., Marcellini M., Devito R., Ciampalini P., Piemonte F., Comparcola D., et al. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology 2006, 44:458-465.
22. de Piano A., Prado W.L., Caranti D.A., Caranti D.A., Siqueira K.O., Stella S.G., et al. Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2007, 44:446-452.
23. Wang C.L., Liang L., Fu J.F., Zou C.C., Hong F., Xue J.Z., et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008, 14:1598-1602.
24. Grønbæk H., Lange A., Birkebæk N.H., Holland-Fischer P., Solvig J., Hørlyck A., et al. Effect of a 10-week weight-loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr 2011, epub ahead of print.
25. Nobili V., Manco M., Devito R., Di Ciommo V., Comparcola D., Sartorelli M.R., et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008, 48:119-128.
26. Nobili V., Alisi A., Raponi M. Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 2009, 15:6017-6022.
27. Mager D.R., Patterson C., So S., Rogenstein C.D., Wykes L.J., Roberts E.A. Dietary and physical activity patterns in children with fatty liver. Eur J Clin Nutr 2010, 64:628-635.
28. Gentile C.L., Pagliassotti M.J. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem 2008, 19:567-576.
29. Harrison S.A., Day C.P. Benefits of lifestyle modification in NAFLD. Gut 2007, 56:1760-1769.
30. Larter C.Z., Chitturi S., Heydet D., Farrell G.C. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 2010, 25:672-690.
31. Lonardo A., Bellentani S., Ratziu V., Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient-death of a dogma from analysis of therapeutic studies?. Expert Rev Gastroenterol Hepatol 2011, 5:279-289.
32. Stein L.L., Dong M.H., Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: current status. Adv Ther 2009, 26:893-907.
33. Nobili V., Manco M., Ciampalini P., Alisi A., Devito R., Bugianesi E., et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008, 30:1168-1176.
34. Nadeau K.J., Ehlers L.B., Zeitler P.S., Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes 2009, 10:5-13.
35. Lavine J.E., Schwimmer J.B., Van Natta M.L., Molleston J.P., Murray K.F., Rosenthal P., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
36. Van Wagner L.B., Rinella M.E. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2011, 4:249-263.
37. Socha P., Horvath A., Vajro P., Dziechciarz P., Dhawan A., Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009, 48:587-596.
38. Alisi A., Locatelli M., Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010, 13:397-402.
39. Nobili V., Manco M., Devito R., Ciampalini P., Piemonte F., Marcellini M. Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006, 24:1553-1561.
40. Vajro P., Franzese A., Valerio G., Iannucci M.P., Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000, 136:739-743.
41. Iacono A., Raso G.M., Canani R.B., Calignano A., Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem 2011, 22:699-711.
42. Masterton G.S., Plevris J.N., Hayes P.C. Review article: omega-3 fatty acids-a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2010, 31:679-692.
43. Abu-Shanab A., Quigley E.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7:691-701.
44. Alisi A., Carsetti R., Nobili V. Pathogen or damaged associated molecular patterns during non-alcoholic fatty liver disease development. Hepatology 2011, 54:1500-1502.
45. Flachs P., Rossmeisl M., Bryhn M., Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acid on adipose tissue biology and metabolism. Cli Sci (Lond) 2009, 116:1-16.
46. Nobili V., Bedogni G., Alisi A., Pietrobattista A., Risé P., Galli C., et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011, 96:350-353.
47. Alisi A., Cianfarani S., Manco M., Agostoni C., Nobili V. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: Pathogenetic role of genetic background and intrauterine environment. Ann Med 2011, epub ahead of print.
48. Tilg H., Moschen A. Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation. Curr Opin Clin Nutr Metab Care 2010, 13:391-396.
49. Duvnjak M., Tomasic V., Gomercic M., Smircic Duvnjak L., Barsic N., Lerotic I. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol 2009, 60(suppl 7):57-66.
50. Georgescu E.F. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?. Adv Ther 2008, 25:1141-1174.